{"entity":{"id":"nct07473128","kind":"trial","name":"Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer","aka":[],"tldr":"A phase 3 trial of Trilaciclib in small-cell lung cancer, run by Pharmacosmos A/S, now recruiting.","summary":"Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07473128 by Pharmacosmos A/S, with 120 participants planned, started 2026-06-30 and due to reach its primary completion in 2027-06. Interventions recorded: Trilaciclib, Saline (0.9% NaCl). Conditions listed: Limited Stage Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07473128","url":"https://clinicaltrials.gov/study/NCT07473128"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["trilaciclib"],"companies":["pharmacosmos"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07473128","phase":"3","setting":"A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer","sponsor":"Pharmacosmos A/S","enrolled":120,"outcomes":[]},"route":"/trials/nct07473128/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"trilaciclib","kind":"drug","name":"Trilaciclib","route":"/drugs/trilaciclib/"}],"company":[{"id":"pharmacosmos","kind":"company","name":"Pharmacosmos","route":"/companies/pharmacosmos/"}]}}